Table 4.

The association of TNFR2 and hsCRP with the risk of rapid decline in mGFR and eGFR in logistic regression models

Rapid GFR DeclineUnadjustedAdjusted for Sex and Baseline Age, Weight, and HeightFully Adjusteda
Odds Ratio95% CIP ValueOdds Ratio95% CIP ValueOdds Ratio95% CIP Value
TNFR2b
 mGFR0.760.47 to 1.210.251.050.63 to 1.730.860.930.53 to 1.630.79
 eGFRcre1.120.69 to 1.930.591.130.67 to 1.920.651.110.62 to 2.000.72
 eGFRcys1.581.08 to 2.310.021.310.81 to 2.120.271.300.78 to 2.180.32
 eGFRcrecys1.090.69 to 1.710.721.060.63 to 1.790.831.000.56 to 1.780.99
hsCRP
 mGFR1.041.01 to 1.070.011.031.01 to 1.060.021.031.00 to 1.070.07
 eGFRcre1.051.02 to 1.080.0011.051.02 to 1.080.0011.051.02 to 1.080.001
 eGFRcys1.020.99 to 1.040.291.010.98 to 1.040.481.010.98 to 1.040.67
 eGFRcrecys1.000.98 to 1.010.721.020.98 to 1.050.321.010.98 to 1.040.55
  • The Renal Iohexol-Clearance Survey Follow-Up Study. The odds ratios represent 1 SD higher TNFR2 and 1 mg/L higher hsCRP. Each row represents separate logistic regression models with rapid decline in mGFR or eGFR (≥3.0 ml/min per 1.73 m2 per year) as a dependent variable. TNFR2, soluble TNF receptor 2; hsCRP, high-sensitivity C-reactive protein; mGFR, measured GFR; 95% CI, 95% confidence interval; eGFRcre, eGFR on the basis of creatinine; eGFRcys, eGFR on the basis of cystatin C; eGFRcrecys, eGFR on the basis of creatinine and cystatin C.

  • a Adjusted for sex; baseline age, weight and height; systolic BP; LDL and HDL cholesterol; fasting triglycerides; hemoglobin A1c; urinary albumin-to-creatinine ratio; number of cigarettes currently smoked; angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or nonsteroidal anti-inflammatory drugs; a dichotomous variable for the weekly use of alcohol; and baseline mGFR or eGFR.

  • b The SD for TNFR2 is 651.5.